Impact of clinical and echocardiographic characteristics on occurrence of cardiac events in cardiac amyloidosis as proven by endomyocardial biopsy

Takuya Nakahashi, Takeshi Arita, Kyohei Yamaji, Katsumi Inoue, Tadaaki Yokota, Yoshinobu Hoshii, Masato Fukunaga, Akihiro Nomura, Hirotoshi Watanabe, Shirou Miura, Akihiro Isotani, Yoshimitsu Soga, Kenji Ando, Masashi Iwabuchi, Hiroyoshi Yokoi, Hideyuki Nosaka, Masakazu Yamagishi, Masakiyo Nobuyoshi

    Research output: Contribution to journalArticle

    9 Citations (Scopus)

    Abstract

    Background Although patients with immunoglobulin light chain (AL) cardiac amyloidosis exhibit worse outcomes than those with transthyretin (TTR) cardiac amyloidosis, few data exist regarding the occurrence of cardiac events and the echocardiographic indices in endomyocardial biopsy (EMBx) proven amyloidosis.

    Methods From November 2007 to October 2012, we identified 33 patients with EMBx-proven amyloidosis. There were 12 patients (8 men; mean age: 66 years) with AL and 21 patients (20 men; mean age: 78 years) with TTR. We performed serial echocardiography and observed the patients during follow-up; defining all-cause mortality as the primary endpoint and hospitalization for heart failure as the secondary endpoint.

    Results The survival rates at 12 months were 20.8% and 85.7% in AL and TTR, respectively (p < 0.001). The cumulative incidences of the composite of death or readmission for heart failure at 12 months were 91.7% and 51.3% in AL and TTR, respectively (p < 0.001). A multivariate analysis showed that the AL type amyloid was the powerful predictor of mortality (hazard ratio: 8.50, 95% confidence interval: 1.79 to 40.57, p < 0.05). Under these conditions, the E/e′ in AL tended to increase from 23 ± 13 to 28 ± 11 (p = 0.06) with marked increases in B-type natriuretic peptide (779 ± 456 pg/ml to 1576 ± 895 pg/ml, p < 0.05), although these remained unchanged in TTR, which exhibited significantly increased left ventricular end-diastolic dimensions from 40 ± 4 mm to 42 ± 4 mm (p < 0.05).

    Conclusions The survival rate was generally worse in AL cardiac amyloidosis, although the readmission for heart failure remains high in TTR cardiac amyloidosis with the occurrence of left ventricular dilatation.

    Original languageEnglish
    Pages (from-to)753-759
    Number of pages7
    JournalInternational Journal of Cardiology
    Volume176
    Issue number3
    DOIs
    Publication statusPublished - Oct 20 2014

    Fingerprint

    Amyloidosis
    Prealbumin
    Biopsy
    Heart Failure
    Survival Rate
    Immunoglobulin Light Chains
    Mortality
    Brain Natriuretic Peptide
    Amyloid
    Echocardiography
    Dilatation
    Hospitalization
    Multivariate Analysis
    Confidence Intervals
    Incidence
    Amyloidosis, Hereditary, Transthyretin-Related

    All Science Journal Classification (ASJC) codes

    • Cardiology and Cardiovascular Medicine

    Cite this

    Impact of clinical and echocardiographic characteristics on occurrence of cardiac events in cardiac amyloidosis as proven by endomyocardial biopsy. / Nakahashi, Takuya; Arita, Takeshi; Yamaji, Kyohei; Inoue, Katsumi; Yokota, Tadaaki; Hoshii, Yoshinobu; Fukunaga, Masato; Nomura, Akihiro; Watanabe, Hirotoshi; Miura, Shirou; Isotani, Akihiro; Soga, Yoshimitsu; Ando, Kenji; Iwabuchi, Masashi; Yokoi, Hiroyoshi; Nosaka, Hideyuki; Yamagishi, Masakazu; Nobuyoshi, Masakiyo.

    In: International Journal of Cardiology, Vol. 176, No. 3, 20.10.2014, p. 753-759.

    Research output: Contribution to journalArticle

    Nakahashi, T, Arita, T, Yamaji, K, Inoue, K, Yokota, T, Hoshii, Y, Fukunaga, M, Nomura, A, Watanabe, H, Miura, S, Isotani, A, Soga, Y, Ando, K, Iwabuchi, M, Yokoi, H, Nosaka, H, Yamagishi, M & Nobuyoshi, M 2014, 'Impact of clinical and echocardiographic characteristics on occurrence of cardiac events in cardiac amyloidosis as proven by endomyocardial biopsy', International Journal of Cardiology, vol. 176, no. 3, pp. 753-759. https://doi.org/10.1016/j.ijcard.2014.07.100
    Nakahashi, Takuya ; Arita, Takeshi ; Yamaji, Kyohei ; Inoue, Katsumi ; Yokota, Tadaaki ; Hoshii, Yoshinobu ; Fukunaga, Masato ; Nomura, Akihiro ; Watanabe, Hirotoshi ; Miura, Shirou ; Isotani, Akihiro ; Soga, Yoshimitsu ; Ando, Kenji ; Iwabuchi, Masashi ; Yokoi, Hiroyoshi ; Nosaka, Hideyuki ; Yamagishi, Masakazu ; Nobuyoshi, Masakiyo. / Impact of clinical and echocardiographic characteristics on occurrence of cardiac events in cardiac amyloidosis as proven by endomyocardial biopsy. In: International Journal of Cardiology. 2014 ; Vol. 176, No. 3. pp. 753-759.
    @article{10d39f9d0c6f4d4fa77d58ce499b13e5,
    title = "Impact of clinical and echocardiographic characteristics on occurrence of cardiac events in cardiac amyloidosis as proven by endomyocardial biopsy",
    abstract = "Background Although patients with immunoglobulin light chain (AL) cardiac amyloidosis exhibit worse outcomes than those with transthyretin (TTR) cardiac amyloidosis, few data exist regarding the occurrence of cardiac events and the echocardiographic indices in endomyocardial biopsy (EMBx) proven amyloidosis.Methods From November 2007 to October 2012, we identified 33 patients with EMBx-proven amyloidosis. There were 12 patients (8 men; mean age: 66 years) with AL and 21 patients (20 men; mean age: 78 years) with TTR. We performed serial echocardiography and observed the patients during follow-up; defining all-cause mortality as the primary endpoint and hospitalization for heart failure as the secondary endpoint.Results The survival rates at 12 months were 20.8{\%} and 85.7{\%} in AL and TTR, respectively (p < 0.001). The cumulative incidences of the composite of death or readmission for heart failure at 12 months were 91.7{\%} and 51.3{\%} in AL and TTR, respectively (p < 0.001). A multivariate analysis showed that the AL type amyloid was the powerful predictor of mortality (hazard ratio: 8.50, 95{\%} confidence interval: 1.79 to 40.57, p < 0.05). Under these conditions, the E/e′ in AL tended to increase from 23 ± 13 to 28 ± 11 (p = 0.06) with marked increases in B-type natriuretic peptide (779 ± 456 pg/ml to 1576 ± 895 pg/ml, p < 0.05), although these remained unchanged in TTR, which exhibited significantly increased left ventricular end-diastolic dimensions from 40 ± 4 mm to 42 ± 4 mm (p < 0.05).Conclusions The survival rate was generally worse in AL cardiac amyloidosis, although the readmission for heart failure remains high in TTR cardiac amyloidosis with the occurrence of left ventricular dilatation.",
    author = "Takuya Nakahashi and Takeshi Arita and Kyohei Yamaji and Katsumi Inoue and Tadaaki Yokota and Yoshinobu Hoshii and Masato Fukunaga and Akihiro Nomura and Hirotoshi Watanabe and Shirou Miura and Akihiro Isotani and Yoshimitsu Soga and Kenji Ando and Masashi Iwabuchi and Hiroyoshi Yokoi and Hideyuki Nosaka and Masakazu Yamagishi and Masakiyo Nobuyoshi",
    year = "2014",
    month = "10",
    day = "20",
    doi = "10.1016/j.ijcard.2014.07.100",
    language = "English",
    volume = "176",
    pages = "753--759",
    journal = "International Journal of Cardiology",
    issn = "0167-5273",
    publisher = "Elsevier Ireland Ltd",
    number = "3",

    }

    TY - JOUR

    T1 - Impact of clinical and echocardiographic characteristics on occurrence of cardiac events in cardiac amyloidosis as proven by endomyocardial biopsy

    AU - Nakahashi, Takuya

    AU - Arita, Takeshi

    AU - Yamaji, Kyohei

    AU - Inoue, Katsumi

    AU - Yokota, Tadaaki

    AU - Hoshii, Yoshinobu

    AU - Fukunaga, Masato

    AU - Nomura, Akihiro

    AU - Watanabe, Hirotoshi

    AU - Miura, Shirou

    AU - Isotani, Akihiro

    AU - Soga, Yoshimitsu

    AU - Ando, Kenji

    AU - Iwabuchi, Masashi

    AU - Yokoi, Hiroyoshi

    AU - Nosaka, Hideyuki

    AU - Yamagishi, Masakazu

    AU - Nobuyoshi, Masakiyo

    PY - 2014/10/20

    Y1 - 2014/10/20

    N2 - Background Although patients with immunoglobulin light chain (AL) cardiac amyloidosis exhibit worse outcomes than those with transthyretin (TTR) cardiac amyloidosis, few data exist regarding the occurrence of cardiac events and the echocardiographic indices in endomyocardial biopsy (EMBx) proven amyloidosis.Methods From November 2007 to October 2012, we identified 33 patients with EMBx-proven amyloidosis. There were 12 patients (8 men; mean age: 66 years) with AL and 21 patients (20 men; mean age: 78 years) with TTR. We performed serial echocardiography and observed the patients during follow-up; defining all-cause mortality as the primary endpoint and hospitalization for heart failure as the secondary endpoint.Results The survival rates at 12 months were 20.8% and 85.7% in AL and TTR, respectively (p < 0.001). The cumulative incidences of the composite of death or readmission for heart failure at 12 months were 91.7% and 51.3% in AL and TTR, respectively (p < 0.001). A multivariate analysis showed that the AL type amyloid was the powerful predictor of mortality (hazard ratio: 8.50, 95% confidence interval: 1.79 to 40.57, p < 0.05). Under these conditions, the E/e′ in AL tended to increase from 23 ± 13 to 28 ± 11 (p = 0.06) with marked increases in B-type natriuretic peptide (779 ± 456 pg/ml to 1576 ± 895 pg/ml, p < 0.05), although these remained unchanged in TTR, which exhibited significantly increased left ventricular end-diastolic dimensions from 40 ± 4 mm to 42 ± 4 mm (p < 0.05).Conclusions The survival rate was generally worse in AL cardiac amyloidosis, although the readmission for heart failure remains high in TTR cardiac amyloidosis with the occurrence of left ventricular dilatation.

    AB - Background Although patients with immunoglobulin light chain (AL) cardiac amyloidosis exhibit worse outcomes than those with transthyretin (TTR) cardiac amyloidosis, few data exist regarding the occurrence of cardiac events and the echocardiographic indices in endomyocardial biopsy (EMBx) proven amyloidosis.Methods From November 2007 to October 2012, we identified 33 patients with EMBx-proven amyloidosis. There were 12 patients (8 men; mean age: 66 years) with AL and 21 patients (20 men; mean age: 78 years) with TTR. We performed serial echocardiography and observed the patients during follow-up; defining all-cause mortality as the primary endpoint and hospitalization for heart failure as the secondary endpoint.Results The survival rates at 12 months were 20.8% and 85.7% in AL and TTR, respectively (p < 0.001). The cumulative incidences of the composite of death or readmission for heart failure at 12 months were 91.7% and 51.3% in AL and TTR, respectively (p < 0.001). A multivariate analysis showed that the AL type amyloid was the powerful predictor of mortality (hazard ratio: 8.50, 95% confidence interval: 1.79 to 40.57, p < 0.05). Under these conditions, the E/e′ in AL tended to increase from 23 ± 13 to 28 ± 11 (p = 0.06) with marked increases in B-type natriuretic peptide (779 ± 456 pg/ml to 1576 ± 895 pg/ml, p < 0.05), although these remained unchanged in TTR, which exhibited significantly increased left ventricular end-diastolic dimensions from 40 ± 4 mm to 42 ± 4 mm (p < 0.05).Conclusions The survival rate was generally worse in AL cardiac amyloidosis, although the readmission for heart failure remains high in TTR cardiac amyloidosis with the occurrence of left ventricular dilatation.

    UR - http://www.scopus.com/inward/record.url?scp=84908231988&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84908231988&partnerID=8YFLogxK

    U2 - 10.1016/j.ijcard.2014.07.100

    DO - 10.1016/j.ijcard.2014.07.100

    M3 - Article

    C2 - 25131905

    AN - SCOPUS:84908231988

    VL - 176

    SP - 753

    EP - 759

    JO - International Journal of Cardiology

    JF - International Journal of Cardiology

    SN - 0167-5273

    IS - 3

    ER -